AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

This trial is testing whether combining an immunotherapy drug (AK104, a dual PD-1/CTLA-4 blocker) with low-dose targeted radiation can help people with recurrent or metastatic head and neck cancer or nasopharyngeal cancer after their first-line treatment has stopped working. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with recurrent or metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma - Your cancer has progressed on first-line treatment (or relapsed within 6 months of radical radiotherapy) - You are in good physical condition (ECOG 0–1) - You have at least one measurable tumor lesion **You may NOT be eligible if...** - You have active brain metastases - You have autoimmune disease requiring systemic treatment - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.